Opthea (ASX:OPT) requested that its securities be placed in trading halt until an announcement related to results of its Phase 3 Combination OPT-302 with Aflibercept Study (COAST) clinical trial is made, according to a Monday filing with the Australian bourse.
The trading halt will remain in place until the start of trading on March 19 or when the company makes the announcement about the COAST results, the filing said.